Page last updated: 2024-12-08

kc 764

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

KC 764: structure given in first source; reduces myocardial infarct size, MPO activity, and the activity of arachidonic acid, thromboxane B2 synthesis, plasma glutamate oxalo-acetate transaminase, lactate dehydrogenase, and creatine kinase [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID146826
SCHEMBL ID114022
MeSH IDM0201198

Synonyms (11)

Synonym
kc-764
kc 764
methanone, (2-methylpyrazolo(1,5-a)pyridin-3-yl)(1,4,5,6-tetrahydro-3-pyridinyl)-
2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo(1,5-a)pyridine
94457-09-7
SCHEMBL114022
2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine
2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)-pyrazolo[1,5-a]pyridine
SLMUMPSLUWOXAO-UHFFFAOYSA-N
DTXSID60241497
kc764

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Serum KC-764 concentration attained the peak in 1 h and declined with a half-life of about 2 h at a single oral dose of 5, 10, 20 and 40 mg."( Pharmacokinetics of the new antiplatelet agent 2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine in human subjects.
Hotta, M; Ishida, R; Kanamaru, M; Komuro, M; Mizuno, A; Nakashima, M; Toriumi, C; Uchida, H; Uematsu, T, 1992
)
0.28

Bioavailability

ExcerptReferenceRelevance
" KC-764 was rapidly and well absorbed by oral administration, and extensively metabolized in all species tested."( Pharmacokinetics of the new antiplatelet agent 2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine in laboratory animals.
Hori, W; Hotta, M; Ishida, R; Komuro, M; Saitoh, S; Uchida, H, 1992
)
0.28

Dosage Studied

ExcerptRelevanceReference
" The urine of animals dosed with 14C-KC-764 was extracted with ethyl acetate after treatment with beta-glucuronidase and arylsulfatase."( Identification of urinary metabolites of 2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine in rat, rabbit and dog.
Ishida, R; Komuro, M; Uchida, H, 1992
)
0.28
"The pharmacokinetics of KC-764 (2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine, CAS 94457-09-7) was studied in healthy male adult volunteers after single ascending oral dose and multiple dosing for 7 days."( Pharmacokinetics of the new antiplatelet agent 2-methyl-3-(1,4,5,6-tetrahydronicotinoyl)pyrazolo[1,5-a]pyridine in human subjects.
Hotta, M; Ishida, R; Kanamaru, M; Komuro, M; Mizuno, A; Nakashima, M; Toriumi, C; Uchida, H; Uematsu, T, 1992
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's9 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.05

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.05 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.05)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (11.11%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]